RxDoctor Payments Data

Nick Mamalis, MD

Ophthalmology · Salt Lake City, UTNPI 1750496220

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $9,663 of the $9,962 with a category attached, or 97.0%. Bausch & Lomb Americas Inc. accounts for 72.5% of it on its own, with 5 other manufacturers making up the rest. 2025 is the largest year on record at $7,277, 4.6 times the $1,593 reported in 2019. Among ophthalmology clinicians in UT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$9,962in general payments, 2019–2025

Across 11 payments — averaging $905.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$7K
  • Johnson & Johnson Surgical Vision, Inc.$2K
  • AbbVie$938
  • Alcon Research LLC$154
  • Alcon$78
  • Carl Zeiss Meditec, Inc.$67
$29,377in research payments, 2019–2025

Across 1 payment — averaging $29,377 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Carl Zeiss Meditec Production LLC$29K

What the payments were for

  • Consulting fees$9,66397%
  • Food & beverage$3003%

General payments by program year

19
20
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,962 in reported general payments places this provider in the 90th percentile of 191 ophthalmology providers in Utah.

See all ophthalmology providers in Utah

Medicare billing

Part B allowed, 2024
$137,647
Medicare patients
1,225
Services billed
1,666

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine108$101,202
Cyclosporine12$3,732
Latanoprost215$2,700
Loteprednol Etabonate20$2,467
Fluorometholone25$1,842
Ketorolac Tromethamine32$1,697
Timolol Maleate45$1,673
Prednisolone Acetate31$1,266
MoxifloxacinMoxifloxacin Hcl29$882
Brimonidine Tartrate24$196

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$938$101,202108 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 191 ophthalmology providers in Utah.

Other ophthalmology in Salt Lake City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →